Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Enlivex Therapeutics Ltd. (ENLV) had Normalized Pre-Tax Income of $-29.07M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-29.07M |
|
-- |
|
-- |
|
$29.39M |
|
$-29.39M |
|
$0.33M |
|
$-29.07M |
|
|
Normalized Pre-Tax Income |
$-29.07M |
$-29.07M |
|
$-29.07M |
|
$-29.07M |
|
$-29.07M |
|
$-29.39M |
|
$-28.56M |
|
18.57M |
|
18.57M |
|
$-1.56 |
|
$-1.56 |
|
| Balance Sheet Financials | |
$33.76M |
|
$1.54M |
|
$3.07M |
|
$36.83M |
|
$6.06M |
|
-- |
|
$0.69M |
|
$6.75M |
|
$30.08M |
|
$30.08M |
|
$30.08M |
|
18.60M |
|
| Cash Flow Statement Financials | |
$-23.52M |
|
$-25.97M |
|
$0.36M |
|
$50.36M |
|
$1.23M |
|
$-49.13M |
|
$1.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-96.62% |
|
-96.62% |
|
-78.92% |
|
-96.62% |
|
$1.62 |
|
$-1.27 |
|
$-1.27 |
|